Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.1400 (0.78%) ($4.9500 - $5.2400) on Fri. Jan. 31, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.7% (three month average) | RSI | 53 | Latest Price | $5.1400(0.78%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.1% a day on average for past five trading days. | Weekly Trend | ADMS declines -3.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) TBT(13%) KWEB(9%) UUP(8%) IBB(7%) BOTZ(6%) | Factors Impacting ADMS price | ADMS will decline at least -3.85% in a week (0% probabilities). BWX(-22%) PCY(-21%) BNDX(-20%) TLT(-17%) EMHY(-17%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.85% (StdDev 7.7%) | Hourly BBV | 0 () | Intraday Trend | 0.8% | | | |
|
Resistance Level | $5.32 | 5 Day Moving Average | $5.22(-1.53%) | 10 Day Moving Average | $5.51(-6.72%) | 20 Day Moving Average | $5.32(-3.38%) | To recent high | -29.6% | To recent low | 0.8% | Market Cap | $145m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |